Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

We recently published a list of Jim Cramer Sees Opportunity in Pessimism and Highlights These 12 Stocks. In this article, we ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

a treatment for bipolar disorder and depression. Management said they now expect sales of $92 billion this year, up from a previous forecast of $91.3 billion. Johnson & Johnson’s cash flow.

Spring books by Minnestans are coming in fast. Here are three authors launching their fiction and nonfiction in post-Easter ...

Jon Hamm hosts a brilliantly funny Saturday Night Live that takes a deep dive into Trump's tariffs, including a look at how ...

The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Johnson & Johnson is increasing its dividend for the 63rd consecutive year. This further cements the healthcare giant's ...